AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3513569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic studies with folic acid-free medium
Number of subjects: 10
Study 3513569 — intervention group
Group type: COMPARATOR
Intervention: Cytogenetic studies with antifolate (methotrexate)
Number of subjects: 10
Study 30580261 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in military camps
Number of subjects: 0
Study 26581834 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32°C)
Number of subjects: 20
Study 26581834 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36°C)
Number of subjects: 20
Study 24351527 — intervention group
Group type: COMPARATOR
Intervention: Standard VTE prophylaxis (5,000 U low‐molecular‐weight heparin daily)
Number of subjects: 50
Study 24351527 — intervention group
Group type: COMPARATOR
Intervention: TEG‐guided prophylaxis (up to 10,000 U low‐molecular‐weight heparin daily)
Number of subjects: 50
Study 24351527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 23167843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX + cetuximab
Number of subjects: 535
Study 23167843 — intervention group
Group type: COMPARATOR
Intervention: Nordic FLOX
Number of subjects: 535
Study 20019197 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help physical activity program (including DSMEP, book 'Manpo-kei', handout, and pedometer)
Number of subjects: 53
Study 20019197 — intervention group
Group type: COMPARATOR
Intervention: Usual Diabetes Self-Management Education Program (DSMEP) only
Number of subjects: 53
Study 20019197 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help physical activity program
Number of subjects: 53
Study 18657960 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 164
Study 18657960 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab (responders)
Number of subjects: 164
Study 16176140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassia tora fiber supplement (2 g of soluble fiber, 200 mg of alpha-tocopherol, 500 mg of ascorbic acid, 300 mg of maltodextrin)
Number of subjects: 15
Study 16176140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassia tora fiber supplement
Number of subjects: 15
Study 16176140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin only)
Number of subjects: 15
Study 12975221 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision-making support (CDS)
Number of subjects: 107
Study 12975221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 10414119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser thermokeratoplasty (LTK) using a laser diode at 1.854 microns, 100 to 150 mW for 10 s, 8 coagulations on a single ring
Number of subjects: 8
Study 10414119 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser thermokeratoplasty (LTK) using a laser diode at 1.87 microns, 100 to 150 mW for 10 s, 16 coagulations on a double ring
Number of subjects: 8
Study 8690639 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 306
Study 8690639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Radiotherapy + Hyperthermia)
Number of subjects: 306
Study 1859764 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 66
Study 1859764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7120436 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour long marital enrichment program (MEP)
Number of subjects: 0
Study 7120436 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control conditions
Number of subjects: 0
Study 30835887 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self‐management (BSM) intervention group
Number of subjects: 60
Study 30835887 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 60
Study 28317507 — intervention group
Group type: EXPERIMENTAL
Intervention: eARM™ training program (hybrid online and in-person)
Number of subjects: 334
Study 28317507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 334
Study 27231170 — intervention group
Group type: COMPARATOR
Intervention: Oxygen intake 7 times/week (D group)
Number of subjects: 263
Study 27231170 — intervention group
Group type: COMPARATOR
Intervention: Oxygen intake 2 times/week (B group)
Number of subjects: 263
Study 27231170 — intervention group
Group type: COMPARATOR
Intervention: Oxygen intake 4 times/week (C group)
Number of subjects: 263
Study 27231170 — intervention group
Group type: COMPARATOR
Intervention: Oxygen intake 2 times/week (A group)
Number of subjects: 263
Study 24759301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie normal protein diet for 6 months
Number of subjects: 26
Study 24759301 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 26
Study 22662729 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention for self-care management; specific details on dosage and duration not available.
Number of subjects: 0
Study 22662729 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecommunications technologies; specific details on dosage and duration not available.
Number of subjects: 0
Study 20648564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 51
Study 17204733 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple Communication Program
Number of subjects: 67
Study 17204733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study 16086615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical features based on the 30-item Inventory of Depressive Symptomatology-Clinician Rating (IDS-C30)
Number of subjects: 1500
Study 16086615 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical parameters
Number of subjects: 1500
Study 12135250 — intervention group
Group type: EXPERIMENTAL
Intervention: IAS pacing in AAIR mode plus antiarrhythmic drugs
Number of subjects: 29
Study 12135250 — intervention group
Group type: COMPARATOR
Intervention: IAS pacing in AAIR mode without antiarrhythmic drugs
Number of subjects: 29
Study 12135250 — intervention group
Group type: EXPERIMENTAL
Intervention: IAS pacing in AAT mode
Number of subjects: 29
Study 12135250 — intervention group
Group type: COMPARATOR
Intervention: Control period (before pacemaker implantation, under antiarrhythmic treatment)
Number of subjects: 29
Study 12135250 — intervention group
Group type: COMPARATOR
Intervention: AAIR pacing mode without antiarrhythmic drugs
Number of subjects: 29
Study 12135250 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIR pacing mode plus antiarrhythmics
Number of subjects: 29
Study 10025887 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli L-asparaginase at 10,000 IU/m2 thrice weekly for nine doses
Number of subjects: 201
Study 10025887 — intervention group
Group type: COMPARATOR
Intervention: Epidoxorubicin at 20 mg/m2 weekly for two doses
Number of subjects: 201
Study 7862469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15 to 20 micrograms/kg
Number of subjects: 48
Study 7862469 — intervention group
Group type: COMPARATOR
Intervention: Placebo lollipop
Number of subjects: 48
Study 2031199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2 + lonidamine 600 mg/day orally
Number of subjects: 12
Study 2031199 — intervention group
Group type: COMPARATOR
Intervention: Vindesin 3 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 12
Study 6284459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 50
Study 6284459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 m sedentary (n = 11)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 m active (n = 8)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 m sedentary (n = 6)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 m active (n = 12)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3500 m sedentary (n = 6)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 3500 m active (n = 8)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 4300 m sedentary (n = 7)
Number of subjects: 66
Study 30439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 4300 m active (n = 8)
Number of subjects: 66
Study 28333757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.03 U/min)
Number of subjects: 0
Study 28333757 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 0
Study 28333757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and Norepinephrine
Number of subjects: 0
Study 28333757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels
Number of subjects: 0
Study 26399503 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanyini GAP intervention
Number of subjects: 94
Study 23714763 — intervention group
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 436
Study 23714763 — intervention group
Group type: COMPARATOR
Intervention: Written discharge instructions
Number of subjects: 436
Study 21558074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based therapy
Number of subjects: 167
Study 19247267 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril/indapamide (2/0.625 mg, daily)
Number of subjects: 62
Study 19247267 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg, daily)
Number of subjects: 62
Study 17512799 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg
Number of subjects: 0
Study 17512799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15145099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta-blockers before PCI (BB+ group)
Number of subjects: 2082
Study 15145099 — intervention group
Group type: COMPARATOR
Intervention: No intravenous beta-blockers before PCI (BB- group)
Number of subjects: 2082
Study 11187220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (bolus dose 0.15 mg/kg followed by continuous infusion)
Number of subjects: 45
Study 11187220 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (bolus dose 0.4 mg/kg followed by continuous infusion)
Number of subjects: 45
Study 9071645 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (hGH) treatment for 2 years
Number of subjects: 48
Study 9071645 — intervention group
Group type: COMPARATOR
Intervention: Comparison sample (not treated with hGH)
Number of subjects: 48
Study 1532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan membrane with bicarbonate buffer
Number of subjects: 22
Study 1532382 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate membrane with bicarbonate buffer
Number of subjects: 22
Study 1532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan membrane with acetate buffer
Number of subjects: 22
Study 1532382 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate membrane with acetate buffer
Number of subjects: 22
Study 3910053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (G.B.E.) 3 X 40 mg/day
Number of subjects: 60
Study 3910053 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline 5 mg
Number of subjects: 60
Study 3910053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31034619 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist MI-consistent skill in the increasing alcohol-CT class
Number of subjects: 164
Study 31034619 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist MI-consistent skill in the low sexual risk-CT class
Number of subjects: 164
Study 29968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric cautery (Group C)
Number of subjects: 80
Study 29968137 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (Group S)
Number of subjects: 80
Study 27099272 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk of aerobic exercise (low dose)
Number of subjects: 0
Study 27099272 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/wk of aerobic exercise (high dose)
Number of subjects: 0
Study 27099272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25254899 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy - 3 min at -110°C
Number of subjects: 13
Study 25254899 — intervention group
Group type: COMPARATOR
Intervention: Control - 3 min at 21°C
Number of subjects: 13
Study 22277570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 302
Study 22277570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 21409296 — intervention group
Group type: EXPERIMENTAL
Intervention: m-DOT strategy
Number of subjects: 234
Study 21409296 — intervention group
Group type: COMPARATOR
Intervention: Standard self-administration of ART
Number of subjects: 234
Study 18178950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment
Number of subjects: 200
Study 18178950 — intervention group
Group type: COMPARATOR
Intervention: Polysporin Triple antibiotic ointment
Number of subjects: 200
Study 16503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) with free patches and intensive instructions from nurses
Number of subjects: 174
Study 16503844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 174
Study 12812919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (titrated to reduce heart rate by 15%)
Number of subjects: 37
Study 12812919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12812919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 37
Study 11059180 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT) - hand immersion in ice water for 1 minute.
Number of subjects: 28
Study 11059180 — intervention group
Group type: COMPARATOR
Intervention: High-chilli diet (approximately 15 g/day) for 3 days.
Number of subjects: 28
Study 8792944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg bid after 72 hours of intravenous antibiotics (group 1)
Number of subjects: 50
Study 8792944 — intervention group
Group type: COMPARATOR
Intervention: Parenteral therapy alone (group 2)
Number of subjects: 50
Study 8792944 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (group 3)
Number of subjects: 50
Study 8792944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (group 1)
Number of subjects: 50
Study 1298468 — intervention group
Group type: EXPERIMENTAL
Intervention: Danggui Funing (DGFN) pill
Number of subjects: 207
Study 1298468 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 207
Study 1298468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 540705 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 22
Study 540705 — intervention group
Group type: COMPARATOR
Intervention: Urografin
Number of subjects: 22
Study 31924516 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair
Number of subjects: 58
Study 31924516 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 58
Study 30907929 — intervention group
Group type: EXPERIMENTAL
Intervention: Superpower Glass intervention plus standard of care applied behavioral analysis therapy
Number of subjects: 71
Study 30907929 — intervention group
Group type: COMPARATOR
Intervention: Applied behavioral analysis therapy (control)
Number of subjects: 71
Study 27836505 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) injectable
Number of subjects: 0
Study 27836505 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 0
Study 27836505 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin contraception
Number of subjects: 0
Study 26401577 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (K-citrate), 40 mEq daily for 1 year
Number of subjects: 83
Study 21890295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0M)
Number of subjects: 136
Study 21890295 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.5M)
Number of subjects: 136
Study 21410944 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dose of methotrexate/day for 5 days
Number of subjects: 25
Study 21410944 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dose of methotrexate
Number of subjects: 25
Study 19710291 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 2925
Study 19710291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2925
Study 17347500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg orally) along with conventional opioid treatment
Number of subjects: 76
Study 17347500 — intervention group
Group type: COMPARATOR
Intervention: Conventional opioid treatment
Number of subjects: 76
Study 16356697 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20‐Hz rTMS to the LPF and 1‐Hz rTMS to the RPF)
Number of subjects: 30
Study 16356697 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS focused on different regions of the brain (20‐Hz rTMS to an area of relatively low activity and 1‐Hz rTMS to an area showing relatively high activation)
Number of subjects: 30
Study 16356697 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study 14687524 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation of 10 ppm
Number of subjects: 12
Study 14687524 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study 10516936 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-delivery formulation of 240 mg diltiazem (DIL)
Number of subjects: 2
Study 10516936 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release formulation of 10 mg felodipine (FEL)
Number of subjects: 2
Study 10516936 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine (AML)
Number of subjects: 2
Study 7706344 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 50
Study 7706344 — intervention group
Group type: COMPARATOR
Intervention: Closed medullary pinning
Number of subjects: 50
Study 7706344 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation and Closed medullary pinning
Number of subjects: 50
Study 1968329 — intervention group
Group type: EXPERIMENTAL
Intervention: Good therapeutic alliance with therapists within the first 6 months of treatment
Number of subjects: 143
Study 1968329 — intervention group
Group type: COMPARATOR
Intervention: Poor therapeutic alliance with therapists
Number of subjects: 143
Study 7423602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid as one effervescent tablet once daily
Number of subjects: 41
Study 7423602 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41
Study 7423602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid
Number of subjects: 41
Study 7423602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of ascorbic acid
Number of subjects: 41
Study 31949012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 303
Study 31949012 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 303
Study 31380690 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 600
Study 31380690 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 600
Study 29301922 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FORM MART
Number of subjects: 1847
Study 29301922 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1847
Study 27402549 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 432
Study 27402549 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 432
Study 27402549 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing stability
Number of subjects: 432
Study 24443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual low-dose CT screening (CT group)
Number of subjects: 4104
Study 24443174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4104
Study 24443174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CT + control)
Number of subjects: 4104
Study 22534465 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/ceCT
Number of subjects: 120
Study 22534465 — intervention group
Group type: COMPARATOR
Intervention: PET/ldCT
Number of subjects: 120
Study 20692602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin-enriched fermented milk (200 mg of lactoferrin daily)
Number of subjects: 36
Study 20692602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fermented milk only)
Number of subjects: 36
Study 17985199 — intervention group
Group type: EXPERIMENTAL
Intervention: Economical stress
Number of subjects: 213
Study 16003295 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM230 (100 microg)
Number of subjects: 12
Study 16003295 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM230 (250 microg)
Number of subjects: 12
Study 16003295 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (100 microg)
Number of subjects: 12
Study 12421057 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory sequences (unimodal)
Number of subjects: 0
Study 12421057 — intervention group
Group type: COMPARATOR
Intervention: Visual sequences (unimodal)
Number of subjects: 0
Study 12421057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal conditions (auditory and visual sequences)
Number of subjects: 0
Study 10353670 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the end of cardiopulmonary bypass (control group)
Number of subjects: 46